Development and characterization of a plant-derived norovirus-like particle vaccine

Shapiro, Janna R.; Andreani, Guadalupe; Dubé, Charlotte; Berubé, Mélanie; Bussière, Diane; Couture, Manon M.-J.; Dargis, Michèle; Hendin, Hilary E.; Landry, Nathalie; Lavoie, Pierre-Olivier; Pillet, Stéphane; Ward, Brian J.; D'Aoust, Marc-André; Trépanier, Sonia

doi:10.1016/j.vaccine.2023.08.036

Cited by 4 publications

(1 citation statement)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been shown that various types of biologics could be produced by plants, including antibodies, vaccines, therapeutic proteins, and cytokines [ 19 , 20 , 21 ]. Plant expression platforms are safe and cost-effective.…”

Section: Introductionmentioning

confidence: 99%

Exploring the Potentiality of a Plant Platform for Monoclonal Antibody Production in Veterinary Medicine

Morel,

Favrot,

Mirande

et al. 2024

Vaccines

View full text Add to dashboard Cite

Canine atopic dermatitis (CAD) is an allergic, inflammatory, and pruritic skin disease associated with the production of IgE antibodies against environmental allergens and mainly house dust mite allergens. This complex dermatological pathology involves Interleukin 31 (IL-31) as a central itch mediator. One of the most effective CAD treatments is a caninized monoclonal antibody (mAb) called Lokivetmab. It is produced in CHO cells and targets specifically canine IL-31 (cIL-31) and blocks its cellular messaging. This treatment has undoubtedly contributed to a breakthrough in dermatitis-related pruritus. However, its production in mammalian cells requires time-consuming procedures, high production costs, and investment. Plants are considered an emerging protein production platform for recombinant biopharmaceuticals due to their cost-effectiveness and rapidity for production. Here, we use transient expression in Nicotiana benthamiana plants to produce recombinant canine Interleukin 31 (cIL-31) and an anti-IL-31 monoclonal antibody (M1). First, we describe the production and characterization of M1 and then its activity on an IL-31-induced pruritic model in dogs compared to its commercial homolog. Dogs treated with the plant-made M1 mAb have shown similar improvements to Lokivetmab-treated ones after different challenges using canine IL-31. Furthermore, M1 injections were not associated with any side effects. These results demonstrate the safety and efficacy of this plant-made Lokivetmab biosimilar to control dogs’ pruritus in a well-established model. Finally, this study shows that the plant-production platform can be utilized to produce rapidly functional mAbs and bring hope to the immunotherapy field of veterinary medicine.

show abstract

Section: Introductionmentioning

confidence: 99%

Exploring the Potentiality of a Plant Platform for Monoclonal Antibody Production in Veterinary Medicine

Morel,

Favrot,

Mirande

et al. 2024

Vaccines

View full text Add to dashboard Cite

show abstract

Plant‐Made Vaccines Targeting Enteric Pathogens—Safe Alternatives for Vaccination in Developing Countries

Trujillo,

Angulo

2024

Biotech & Bioengineering

View full text Add to dashboard Cite

Enteric diseases by pathogenic organisms are one of the leading causes of death worldwide, particularly in low‐income countries. Despite antibiotics, access to clean water and vaccination are the most economically affordable options to prevent those infections and their health consequences. Vaccines, such as those approved for rotavirus and cholera, have played a key role in preventing several enteric diseases. However, vaccines for other pathogens are still in clinical trials. Distribution and cost remain significant barriers to vaccine access in developing regions due to poor healthcare infrastructure, cold‐chain requirements, and high production costs. Plant‐made vaccines offer a promising alternative to address these challenges. Plants can be easily grown, lowering production costs, and can be administered in oral forms, potentially eliminating cold‐chain dependency. Although there are some promising prototypes of vaccines produced in plants, challenges remain, including yields and achieving sufficient immunogenicity. This review aims to describe common enteric pathogens and available vaccines, followed by a strategic summary of plant‐made vaccine development and a discussion of plant‐made enteric vaccine prototypes. Trends to overcome the key challenges for plant‐made vaccines are identified and placed in perspective for the development of affordable and effective vaccines for populations at the highest risk of enteric diseases.

show abstract

Application of hairy root culture in therapeutics

Singh,

Dwivedi,

Pandita

et al. 2025

Medicinal Biotechnology

View full text Add to dashboard Cite

Development and characterization of a plant-derived norovirus-like particle vaccine

Cited by 4 publications

References 56 publications

Exploring the Potentiality of a Plant Platform for Monoclonal Antibody Production in Veterinary Medicine

Exploring the Potentiality of a Plant Platform for Monoclonal Antibody Production in Veterinary Medicine

Plant‐Made Vaccines Targeting Enteric Pathogens—Safe Alternatives for Vaccination in Developing Countries

Application of hairy root culture in therapeutics

Contact Info

Product

Resources

About